Next Article in Journal
Doctor’s Preference in Providing Medical Service for Patients in the Medical Alliance: A Pilot Discrete Choice Experiment
Previous Article in Journal
What Protects Youth Residential Caregivers from Burning Out? A Longitudinal Analysis of Individual Resilience
Previous Article in Special Issue
Effect of Chemotherapy, Laparoscopy, and Cytology on Stage IC Ovarian Clear Cell Carcinoma: A Long-Term, Single-Center Study
Open AccessArticle

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer

by Chen-Yu Huang 1,2,3, Min Cheng 1,2,3, Na-Rong Lee 1,4, Hsin-Yi Huang 5, Wen-Ling Lee 3,6,7, Wen-Hsun Chang 1,3,4,* and Peng-Hui Wang 1,2,3,8,9,*
1
Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 112, Taiwan
2
Department of Obstetrics and Gynecology, National Yang-Ming University, Taipei 112, Taiwan
3
Institute of Clinical Medicine, National Yang-Ming University, Taipei 112, Taiwan
4
Department of Nursing, Taipei Veterans General Hospital, Taipei 112, Taiwan
5
Biostatics Task Force, Taipei Veterans General Hospital, Taipei 112, Taiwan
6
Department of Medicine, Cheng-Hsin General Hospital, Taipei 112, Taiwan
7
Department of Nursing, Oriental Institute of Technology, New Taipei City 220, Taiwan
8
Department of Medical Research, China Medical University Hospital, Taichung 440, Taiwan
9
Female Cancer Foundation, Taipei 104, Taiwan
*
Authors to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2020, 17(7), 2213; https://doi.org/10.3390/ijerph17072213
Received: 12 February 2020 / Revised: 20 March 2020 / Accepted: 24 March 2020 / Published: 26 March 2020
(This article belongs to the Special Issue Gynecological Cancer)
The use of weekly chemotherapy for the treatment of patients with advanced-stage serous-type epithelial Tubo-ovarian cancer (ETOC), and primary peritoneal serous carcinoma (PPSC) is acceptable as the front-line postoperative chemotherapy after primary cytoreductive surgery (PCS). The main component of dose-dense chemotherapy is weekly paclitaxel (80 mg/m2), but it would be interesting to know what is the difference between combination of triweekly cisplatin (20 mg/m2) or triweekly carboplatin (carboplatin area under the curve 5-7 mg/mL per min [AUC 5-7]) in the dose-dense paclitaxel regimen. Therefore, we compared the outcomes of women with Gynecology and Obstetrics (FIGO) stage IIIC ETOC and PPSC treated with PCS and a subsequent combination of dose-dense weekly paclitaxel and triweekly cisplatin (paclitaxel–cisplatin) or triweekly carboplatin using AUC 5 (paclitaxel–carboplatin). Between January 2010 and December 2016, 40 women with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC EOC, FTC, or PPSC were enrolled, including 18 treated with paclitaxel–cisplatin and the remaining 22 treated with paclitaxel–carboplatin. There were no statistically significant differences in disease characteristics of patients between two groups. Outcomes in paclitaxel–cisplatin group seemed to be little better than those in paclitaxel–carboplatin (median progression-free survival [PFS] 30 versus 25 months as well as median overall survival [OS] 58.5 versus 55.0 months); however, neither reached a statistically significant difference. In terms of adverse events (AEs), patients in paclitaxel–carboplatin group had more AEs, with a higher risk of neutropenia and grade 3/4 neutropenia, and the need for a longer period to complete the front-line chemotherapy, and the latter was associated with worse outcome for patients. We found that a period between the first-time chemotherapy to the last dose (6 cycles) of chemotherapy >21 weeks was associated with a worse prognosis in patients compared to that ≤21 weeks, with hazard ratio (HR) of 81.24 for PFS and 9.57 for OS. As predicted, suboptimal debulking surgery (>1 cm) also contributed to a worse outcome than optimal debulking surgery (≤1 cm) with HR of 14.38 for PFS and 11.83 for OS. Based on the aforementioned findings, both regimens were feasible and effective, but maximal efforts should be made to achieve optimal debulking surgery and following the on-schedule administration of dose-dense weekly paclitaxel plus triweekly platinum compounds. Randomized trials validating the findings are warranted. View Full-Text
Keywords: dose-dense weekly paclitaxel; epithelial tubo-ovarian cancer; FIGO stage IIIC; primary peritoneal serous carcinoma; triweekly carboplatin; triweekly cisplatin dose-dense weekly paclitaxel; epithelial tubo-ovarian cancer; FIGO stage IIIC; primary peritoneal serous carcinoma; triweekly carboplatin; triweekly cisplatin
Show Figures

Figure 1

MDPI and ACS Style

Huang, C.-Y.; Cheng, M.; Lee, N.-R.; Huang, H.-Y.; Lee, W.-L.; Chang, W.-H.; Wang, P.-H. Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer. Int. J. Environ. Res. Public Health 2020, 17, 2213.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop